Lavipharm S.A. (BXA0.F)
Frankfurt · EUR · Healthcare · Drug Manufacturers - Specialty & Generic
€1.44 (+1.26%) as of
Key statistics
- Market cap
- 246.60M
- P/E (TTM)
- 48.13
- EPS (TTM)
- 0.0300
- Dividend yield
- 1.46%
- 52-week range
- 0.7060 – 1.8500
- Beta
- 1.01
- Revenue (TTM)
- 70.31M
- Profit margin
- 8.17%
- Volume
- 1.00k
About Lavipharm S.A.
Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, cosmetics, and healthcare products to physicians and pharmacists in Greece and internationally. The company offers pharmaceutical products for cardiology, oncology-urology, central nervous system, chronic pain, and self- treatment. It also provides prescription medicines and over the counter (OTC) products, as well as LIFELAB CBD products. The company was founded in 1911 and is based in Paiania, Greece.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Paiania, Greece
- Employees
- 306
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.